Harrow (HROW) Stock Price, News & Analysis

Company Overview

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Key Stats

• Today's Range: $30.46 to $31.64
• 50-Day Range: $22.91 to $31.71
• 52-Week Range: $20.36 to $59.23
• Volume: 449,935 shs
• Average Volume: 494,484 shs
• Market Capitalization: $1.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $61.40
• Consensus Rating: Buy

Harrow Stock Analysis - MarketRank™

Harrow scored higher than 54% of companies evaluated by MarketBeat, and ranked 526th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Harrow has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Harrow has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Harrow are expected to grow in the coming year, from ($0.53) to $0.40 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Harrow is -54.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harrow is -54.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Harrow has a P/B Ratio of 15.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.04% of the float of Harrow has been sold short.

Short Interest Ratio / Days to Cover

Harrow has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Harrow has recently decreased by 3.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harrow does not currently pay a dividend.

Dividend Growth

Harrow does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.04% of the float of Harrow has been sold short.

Short Interest Ratio / Days to Cover

Harrow has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Harrow has recently decreased by 3.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.50

News Sentiment

Harrow has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Harrow this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harrow insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.67% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HROW Stock Analysis - Frequently Asked Questions

How have HROW shares performed this year?

Harrow's stock was trading at $33.55 on January 1st, 2025. Since then, HROW stock has decreased by 9.0% and is now trading at $30.54.
View the best growth stocks for 2025 here.

How were Harrow's earnings last quarter?

Harrow, Inc. (NASDAQ:HROW) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by $0.40. The business had revenue of $47.83 million for the quarter, compared to analysts' expectations of $57 million. Harrow had a negative net margin of 10.19% and a negative trailing twelve-month return on equity of 25.01%.
Read the conference call transcript.

How do I buy shares of Harrow?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Harrow own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:HROW
• Previous Symbol: NASDAQ:HROW
• CIK: 1360214
• Web: www.harrowinc.com
• Phone: (615) 733-4730
• Fax: 858-345-1745
• Employees: 182
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $61.40
• High Stock Price Target: $65.00
• Low Stock Price Target: $55.00
• Potential Upside/Downside: +95.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.48 million
• Net Margins: -10.19%
• Pretax Margin: -10.12%
• Return on Equity: -25.01%
• Return on Assets: -4.27%

Debt

• Debt-to-Equity Ratio: 2.01
• Current Ratio: 0.91
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $199.61 million
• Price / Sales: 5.77
• Cash Flow: $0.14 per share
• Price / Cash Flow: 225.83
• Book Value: $1.95 per share
• Price / Book: 16.11

Miscellaneous

• Outstanding Shares: 36,690,000
• Free Float: 31,670,000
• Market Cap: $1.15 billion
• Optionable: Optionable
• Beta: 0.40